iShares Nasdaq US Biotechnology/$BTEC

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About BTEC ETF

The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. The Index measures the performance of companies listed on the NASDAQ Stock Market that are classified as either biotechnology companies or pharmaceutical companies, according to their Industry Classification Benchmark (ICB) and that also meet other eligibility criteria as determined by NASDAQ, Inc. (the Index Provider), including minimum market capitalisation and liquidity requirements.

Ticker

$BTEC

Fund name

iShares Nasdaq US Biotechnology

Primary listing

LSE
Fund Manager
BlackRock
Share currency
USD

Benchmark

NASDAQ Biotechnology Index (Net Total Return)

Base currency

USD

Risk

6
Documents
Key information documentCosts disclosure document

BTEC Metrics

$895m
0.92

BTEC Fund Highlights

This fund aims to track the Nasdaq Biotechnology index, which covers Nasdaq listed companies primarily engaged in biomedical research to develop new treatments and cures for human disease.
5.07%
Accumulating

0.35%

0.75%

0.03%

BTEC Fund Breakdown

Top holdingsSectorsCountries
Vertex Pharmaceuticals

8.02%

Amgen

7.97%

Gilead Sciences

7.32%

Regeneron

4.76%

Alnylam Pharmaceuticals

2.81%

Revolution Medicines

2.63%

Biogen

2.20%

Moderna

1.92%

Illumina

1.86%

Other

60.51%

Other funds tracking NASDAQ Biotechnology Index (Net Total Return)

Fund name
Fund size
Annual fund charges
iShares Nasdaq US Biotechnology
£BTEK·Acc·GBP
£676m
0.35%
Compare
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.